JY
VERA icon

Jeff Yass’s Vera Therapeutics VERA Stock Holding History

Jeff Yass’s Portfolio VERA Stock Details VERA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.9M Buy
160,837
+39,817
+33% +$1.48M ﹤0.01% 4022
2026
Q1 		$4.87M Sell
121,020
-55,664
-32% -$2.4M ﹤0.01% 4278
2025
Q4 		$8.95M Buy
176,684
+110,077
+165% +$3.91M ﹤0.01% 3208
2025
Q3 		$1.94M Buy
66,607
+5,042
+8% +$117K ﹤0.01% 5861
2025
Q2 		$1.45M Sell
61,565
-39,714
-39% -$893K ﹤0.01% 6531
2025
Q1 		$2.43M Buy
101,279
+74,460
+278% +$2.39M ﹤0.01% 5104
2024
Q4 		$1.13M Buy
26,819
+7,135
+36% +$316K ﹤0.01% 6639
2024
Q3 		$870K Buy
19,684
+8,575
+77% +$325K ﹤0.01% 7132
2024
Q2 		$402K Sell
11,109
-11,434
-51% -$454K ﹤0.01% 8783
2024
Q1 		$972K Sell
22,543
-2,525
-10% -$90K ﹤0.01% 6983
2023
Q4 		$386K Buy
25,068
+5,767
+30% +$73.2K ﹤0.01% 9276
2023
Q3 		$265K Buy
19,301
+7,621
+65% +$131K ﹤0.01% 9635
2023
Q2 		$187K Sell
11,680
-17,670
-60% -$160K ﹤0.01% 10343
2023
Q1 		$228K Buy
+29,350
New +$227K ﹤0.01% 10322

Other funds holding VERA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jeff Yass's VERA Position: Q2 2026 in Review

Jeff Yass increased its Vera Therapeutics (VERA) stake by 33% in Q2 2026, buying an estimated $1.48M and bringing the position to 160,837 shares worth $6.9M. The position accounts for ﹤0.01% of the portfolio, ranked #4022.

Jeff Yass first reported a position in VERA in Q1 2023 and has held it in 14 quarters since. The position peaked at $8.95M in Q4 2025. 218 funds tracked by Wall St. Rank hold VERA as of Q2 2026.

  • Jeff Yass held 160,837 shares of Vera Therapeutics worth $6.9M as of Q2 2026.
  • Jeff Yass bought 39,817 Vera Therapeutics shares in Q2 2026, an estimated $1.48M.
  • Vera Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #4022 holding.
  • Jeff Yass first reported a position in Vera Therapeutics in Q1 2023 and has held it in 14 quarters since.
  • Jeff Yass's Vera Therapeutics position peaked at $8.95M in Q4 2025.
  • 218 funds tracked by Wall St. Rank held Vera Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.